Sandoz launches new global health inequalities initiative
‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
Biosimilar company Sandoz has announced the launch of a new global initiative to take on worldwide health inequities.
Act4Biosimilars aims to increase patient access to advanced medicines by leveraging the ‘4 As’ of biosimilars – approvability, accessibility, acceptability and affordability. The initiative is supported by a multidisciplinary steering committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from across the world.
Other notable targets of the project include ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development. The ultimate goal is to increase global adoption of biosimilar medicines by at least 30% throughout 30 countries by 2030.
Read more: https://www.pharmatimes.com/news/sandoz_launches_new_global_health_inequalities_initiative_1449438
Biosimilar company Sandoz has announced the launch of a new global initiative to take on worldwide health inequities.
Act4Biosimilars aims to increase patient access to advanced medicines by leveraging the ‘4 As’ of biosimilars – approvability, accessibility, acceptability and affordability. The initiative is supported by a multidisciplinary steering committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from across the world.
Other notable targets of the project include ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development. The ultimate goal is to increase global adoption of biosimilar medicines by at least 30% throughout 30 countries by 2030.
Read more: https://www.pharmatimes.com/news/sandoz_launches_new_global_health_inequalities_initiative_1449438
